Evidence map›Paper›PMID 39369049›Full record

ArticleScientific reports2024

Effects of SZV-2649, a new multiple ion channel inhibitor mexiletine analogue.

Aiman Saleh A Mohammed, Muhammad Naveed, Tamara Szabados, István Szatmári, Bálint Lőrinczi, Péter Mátyus, Andrea Czompa, Péter Orvos, Zoltán Husti, Tibor Hornyik and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Aiman Saleh A MohammedDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Muhammad NaveedDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Tamara SzabadosDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
István SzatmáriInstitute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Bálint LőrincziInstitute of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Szeged, Szeged, Hungary.
Péter MátyusDepartment of Organic Chemistry, Semmelweis University, Budapest, Hungary.
Andrea CzompaDepartment of Organic Chemistry, Semmelweis University, Budapest, Hungary.
Péter OrvosDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Zoltán HustiDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Tibor HornyikDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Leila TopalDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Szilvia DériDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Norbert JostDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
László VirágDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Péter BencsikDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
István BaczkóDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. baczko.istvan@med.u-szeged.hu.
András VarróDepartment of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary. varro.andras@med.u-szeged.hu.

Funding

Hungarian Academy of Sciences, János Bolyai Research Scholarships bo_481_21Hungarian Research Network HUN-REN TKI projectMinistry for Innovation and Technology, Cooperative Doctoral Programme KDP-2020Ministry of Human Capacities Hungary EFOP-3.6.2-16-2017-00006, the UNKP for young researchers, UNKP-23-5-SZTE-704National Heart Laboratory, Hungary RRF-2.3.1-21-2022-00003National Research Development and Innovation Office NKFIH K 135464, K 142738, K 147212 TKP2021-EGA-32, FK 138223, GINOP-2.3.2.-15-2016-00006, GINOP-2.3.2.-15-2016-00040Recovery and Resilience Facility (RRF) RRF-2.3.1-21-2022-00001The Albert Szent-Györgyi Medical School institutional grant SZTE AOK-KKA 2021, SZGYA 2021, SZTE AOK-KKA 2022
6 · The paper itself

Abstract

The antiarrhythmic and cardiac electrophysiological effects of SZV-2649 that contains a 2,6-diiodophenoxy moiety but lacks the benzofuran ring system present in amiodarone, were studied in mammalian cell line, rat and dog cardiac preparations. SZV-2649 exerted antiarrhythmic effects against coronary artery occlusion/reperfusion induced ventricular arrhythmias in rats and in acetylcholine- and burst stimulation induced atrial fibrillation in dogs. SZV-2649 inhibited hERG and GIRK currents in HEK cells (IC

Indexed as

Action PotentialsAnti-Arrhythmia AgentsMexiletineAnimalsArrhythmias, CardiacAtrial FibrillationDogsHEK293 CellsHumansMaleMyocytes, CardiacRatsAnti-Arrhythmia AgentsMexiletine

Identifiers

PMID39369049
PMCPMC11455950

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.